Hypertension Patents (Class 514/15.7)
-
Patent number: 11672841Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.Type: GrantFiled: October 30, 2020Date of Patent: June 13, 2023Assignee: STEALTH BIOTHERAPEUTICS INC.Inventor: D. Travis Wilson
-
Patent number: 11353448Abstract: Methods and compositions for quantifying the cellular concentration of cyclic adenosine monophosphate (cAMP), cyclic guanine monophosphate (cGMP), glutathione, glucose, and glutamine in a single cell include the use of conjugates and analogs in immunofluorescent assays for on-chip quantification. These metabolite immunofluorescent assays may be incorporated with proteomic assays for simultaneous single cell analysis of metabolites and proteins.Type: GrantFiled: February 16, 2016Date of Patent: June 7, 2022Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Min Xue, Wei Wei, James R. Heath
-
Patent number: 10632129Abstract: This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof.Type: GrantFiled: November 15, 2015Date of Patent: April 28, 2020Assignee: SteadyMed Ltd.Inventors: Jonathan Rigby, Peter Noymer, Robert Zwolinski
-
Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
Patent number: 10368774Abstract: A health care system acquires data determines whether a patient is at risk of hypervolemia or hypovolemia. The method comprises (a) acquiring from a device memory a patient's absolute intrathoracic impedance data over a pre-specified time period, (b) determining a running average of the intrathoracic impedance data over the pre-specified time period, and (c) determining by the system whether the running average of the intrathoracic impedance data over the pre-specified time period exceeds one of a first and second range, the first range being a higher value boundary of intrathoracic electrical impedance and the second range being a lower value boundary of intrathoracic electrical impedance.Type: GrantFiled: July 28, 2016Date of Patent: August 6, 2019Assignee: Medtronic, Inc.Inventors: Vinod Sharma, Jodi L Redemske -
Patent number: 10082506Abstract: The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including Streptococcus pneumonia, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumonia and Yersinia pestis. This interaction can be targeted to identify, purify and therapeutically target such organisms.Type: GrantFiled: November 5, 2015Date of Patent: September 25, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Laura L. Kiessling, Darryl A. Wesener, Kittikhun Wangkanont
-
Patent number: 9572856Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.Type: GrantFiled: December 16, 2009Date of Patent: February 21, 2017Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir Chawla
-
Patent number: 9181281Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.Type: GrantFiled: November 26, 2013Date of Patent: November 10, 2015Assignee: SineVir Therapeutics LLCInventors: John Hilfinger, Gordon Amidon
-
Patent number: 9045524Abstract: The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.Type: GrantFiled: May 21, 2010Date of Patent: June 2, 2015Assignee: NOVAGENESIS FOUNDATIONInventors: Jan-Eric Ahlfors, Khalid Mekouar
-
Patent number: 9034824Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: July 3, 2014Date of Patent: May 19, 2015Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 9029505Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: GrantFiled: August 16, 2010Date of Patent: May 12, 2015Assignee: Phasebio Pharmaceuticals, Inc.Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
-
Patent number: 9029327Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: GrantFiled: July 23, 2010Date of Patent: May 12, 2015Assignee: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Publication number: 20150126432Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.Type: ApplicationFiled: May 9, 2013Publication date: May 7, 2015Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
-
Publication number: 20150119332Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.Type: ApplicationFiled: November 14, 2013Publication date: April 30, 2015Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventor: Matthew A. Movsesian
-
Publication number: 20150111829Abstract: The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.Type: ApplicationFiled: June 6, 2012Publication date: April 23, 2015Applicant: PHASEBIO PHARMACEUTICALS, INC.Inventors: Lynne M. Georgopoulos, Susan Arnold
-
Publication number: 20150065424Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Applicant: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Publication number: 20150030594Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
-
Publication number: 20150031604Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
-
Patent number: 8940685Abstract: The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical.Type: GrantFiled: May 14, 2013Date of Patent: January 27, 2015Assignee: China National Research Institute of Food and Fermentation IndustriesInventors: Muyi Cai, Ruizeng Gu, Weixue Yi, Jun Lu, Yong Ma, Zhe Dong, Yaguang Xu, Xingchang Pan, Yongqing Ma, Feng Lin, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu
-
Patent number: 8937039Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: GrantFiled: November 15, 2013Date of Patent: January 20, 2015Assignee: The Medical College of Wisconsin, Inc.Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
-
Publication number: 20150018278Abstract: The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4.Type: ApplicationFiled: November 15, 2012Publication date: January 15, 2015Inventor: Jose Maria Frade Lopez
-
Publication number: 20150010531Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.Type: ApplicationFiled: July 31, 2014Publication date: January 8, 2015Applicant: ANNEXIN PHARMACEUTICALS ABInventors: Johan FROSTEGÅRD, Knut PETTERSSON
-
Patent number: 8921306Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.Type: GrantFiled: June 7, 2011Date of Patent: December 30, 2014Assignee: The University of QueenslandInventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
-
Patent number: 8916523Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: GrantFiled: May 28, 2013Date of Patent: December 23, 2014Assignee: Vectus Biosystems LimitedInventor: Karen Annette Duggan
-
Patent number: 8916517Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: GrantFiled: November 2, 2010Date of Patent: December 23, 2014Assignee: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Publication number: 20140370034Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.Type: ApplicationFiled: July 6, 2014Publication date: December 18, 2014Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Publication number: 20140357549Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.Type: ApplicationFiled: May 13, 2014Publication date: December 4, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Daniel J. Ranayhossaini, Patrick Joseph Pagano
-
Publication number: 20140348850Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.Type: ApplicationFiled: August 15, 2014Publication date: November 27, 2014Inventors: Edward P. Feener, Allen Clermont
-
Patent number: 8883145Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: GrantFiled: October 18, 2010Date of Patent: November 11, 2014Assignee: Oncomed Pharmaceuticals, Inc.Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Publication number: 20140329738Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.Type: ApplicationFiled: March 28, 2014Publication date: November 6, 2014Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Patent number: 8865155Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: September 27, 2012Date of Patent: October 21, 2014Assignees: Centro de Investigacion en Alimentacion y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, José Carlos Rodríguez Figueroa
-
Publication number: 20140303068Abstract: The present invention relates generally to a method of reducing unwanted airway tissue mucus secretion in a mammal and to agents useful for same. More particularly, the present invention relates to a method of reducing airway tissue mucus hypersecretion in a mammal by downregulating the functional level of activin or upregulating the functional level of follistatin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by airway tissue mucus dysfunction, such as overproduction of mucus or decreased mucus clearance, and where a reduction in mucus secretion levels would thereby alleviate the condition.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Robyn O'Hehir, Charles Hardy, David De Kretser
-
Publication number: 20140296150Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: ApplicationFiled: August 10, 2012Publication date: October 2, 2014Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 8822413Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: GrantFiled: July 7, 2008Date of Patent: September 2, 2014Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140221271Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.Type: ApplicationFiled: June 5, 2012Publication date: August 7, 2014Inventors: Shawn P Iadonato, Eric J Tarcha
-
Patent number: 8785386Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: September 24, 2013Date of Patent: July 22, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Patent number: 8765677Abstract: This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine; Xaa2 is selected from arginine and lysine; Xaa5 is selected from aspartic acid and glutamic acid; and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.Type: GrantFiled: September 21, 2010Date of Patent: July 1, 2014Assignees: The University of Queensland, The University of SydneyInventors: Richard Lewis, David John Adams, Geza Berecki, Roger Drinkwater, Paul Francis Alewood, MacDonald James Christie
-
Patent number: 8759291Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: April 5, 2011Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Andrew A. Young, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20140155315Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: November 18, 2013Publication date: June 5, 2014Applicant: NOVARTIS AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Patent number: 8741861Abstract: The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.Type: GrantFiled: March 27, 2009Date of Patent: June 3, 2014Assignee: Vascular BiosciencesInventor: David M. Mann
-
Publication number: 20140142022Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Inventors: Frederic ZECRI, Andrei GOLOSOV, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Qi-Ying HU, Hidetomo IMASE, David Thomas PARKER
-
Publication number: 20140127235Abstract: Disclosed herein are novel methods for controlling blood pressure that involve targeting HK alpha. Also, disclosed are novel compositions for treating elevated blood pressure that include administering an agent that disrupts HK alpha expression or activity. Methods of screening novel antihypertensives are disclosed as well.Type: ApplicationFiled: April 6, 2012Publication date: May 8, 2014Inventor: Charles Wingo
-
Publication number: 20140100166Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: September 24, 2013Publication date: April 10, 2014Applicants: University of Washington, Cornell UniversityInventors: Hazel H. Szeto, Peter S. Rabinovitch, Dao-Fu Dai
-
Publication number: 20140094409Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.Type: ApplicationFiled: September 19, 2013Publication date: April 3, 2014Inventor: Yumei FENG
-
Patent number: 8673847Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: GrantFiled: October 5, 2010Date of Patent: March 18, 2014Assignee: The Medical College of Wisconsin, Inc.Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
-
Publication number: 20140072650Abstract: Disclosed is an antihypertensive composition containing as an active ingredient a gelatin extract made from the skins of a skate ray and a peptide isolated from the extract. The present invention is directed to a pharmaceutical composition for a hypertension prevention and therapy containing as an active ingredient a hydrolysate of a gelatin extract isolated from the skins of a skate ray, a method for preparing a hydrolysate of a gelatin extract made from the skins of a skate ray, and the use of a new peptide having an antihypertensive activity isolated and purified from the hydrolysate.Type: ApplicationFiled: October 31, 2012Publication date: March 13, 2014Applicant: Pukyong National University Industry-University Cooperation FoundationInventors: Se-Kwon KIM, Bo-Mi RYU
-
Patent number: 8669229Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: June 26, 2008Date of Patent: March 11, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Publication number: 20140018296Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicant: Alcon Research, Ltd.Inventor: Jon E. Chatterton
-
Publication number: 20140018286Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicant: NOVO NORDISK A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140011737Abstract: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.Type: ApplicationFiled: July 3, 2013Publication date: January 9, 2014Applicant: MAINE MEDICAL CENTERInventor: Volkhard Lindner